Navigation Links
Serina Therapeutics Announces Agreement with the Scripps Research Institute for Development of Polymer-Antibody Drug Conjugates
Date:7/31/2013

HUNTSVILLE, Ala., July 31, 2013 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development, announced today that the company has entered into a research agreement with the Scripps Research Institute for development of polymer-antibody drug conjugates (Polymer-ADCs). The nature of the agreement and the financial terms were not disclosed.

"Antibody drug conjugates represent one of the most exciting areas of drug development in oncology," according to Dr. Randall Moreadith, President and Chief Executive Officer of Serina Therapeutics, Inc. "The ability to target antibodies that are "pay-loaded" with a potent cytotoxic agent has started to produce the first generation of approved antibody drug conjugates. Our polymer technology platform is uniquely suited to advance this field. We are very excited about working with some of the premier antibody scientists in the world at the Scripps Research Institute to develop next-generation ADCs."

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms.  The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners.  Besides developing its own pipeline of pharmaceutical products for Parkinson's disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.  

For more information on Serina Therapeutics, please visit

SOURCE Serina Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
2. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
3. Advanced Prenatal Therapeutics Appoints Dr. Nihar Nayak to its Scientific Advisory Board
4. Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614
5. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
6. Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
7. Frost & Sullivan: Molecular Farming Fits Need for Fully Functional Protein Therapeutics and Low-Cost Vaccines
8. Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis
9. Distinguished Cancer Investigator, Daniel Von Hoff, M.D., to Lead Cell Therapeutics Scientific Advisory Board
10. Cell Therapeutics to Report Second Quarter Financial Results after Market on July 31, 2013
11. Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... PALO ALTO, Calif., March 8, 2011 Jazz Pharmaceuticals, Inc. ... will be providing a business update at two upcoming investor ... financial officer, will provide an update at the ROTH 23rd ... Monday, March 14, 2011 at 4:30 p.m. Pacific Time ...
... Warner Chilcott plc (Nasdaq: WCRX ) ... its ordinary shares by certain selling shareholders. The selling ... Morgan Partners (advised by CCMP Capital) and Thomas H. ... management. The offering is being conducted as a public ...
Cached Medicine Technology:Warner Chilcott Announces Secondary Equity Offering 2Warner Chilcott Announces Secondary Equity Offering 3Warner Chilcott Announces Secondary Equity Offering 4
(Date:4/17/2014)... The presence of chronic inflammation in benign prostate ... cancer, and this association was found even in ... to a study published in Cancer Epidemiology, ... American Association for Cancer Research. , An analysis ... of the placebo arm of the Prostate Cancer ...
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
(Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2
... ... implicate the purchaser in any lawsuit or cause such purchasers to be a party ... ... highly respected developer and manufacturer of proprietary skin care formulations, who also is the ...
... ... latest version of its revolutionary cost-cutting software. Newly developed upgrades to iCodeRx, iDocs, and ... processes, while providing the highest security possible to patient information. , ... Virginia Beach, VA (PRWEB) - DOMA ...
... ... a new agreement with B. E. Smith for Executive Leadership Solutions. , ... Lenexa, KS (Vocus) September 24, ... agreement with B. E. Smith for Executive Leadership Solutions., , ,Effective immediately, through August ...
... trials, advanced cancers shrunk rapidly, researchers say , THURSDAY, ... advanced melanoma promotes rapid shrinking of tumors, according to ... includes patients with the cancer-causing mutation of the BRAF ... melanomas and 5 percent of colorectal cancers. , The ...
... say , THURSDAY, Sept. 24 (HealthDay News) -- Surgery ... carpal tunnel syndrome who don,t have severe nerve damage ... 44 patients who had surgery and 52 patients who ... A year after treatment, the patients, hand function was ...
... drugs increase the possibility of septal malformation, researchers find ... who take certain antidepressants during the first three months ... giving birth to babies with heart defects. , Septal ... right side of the heart from the left -- ...
Cached Medicine News:Health News:Purchase PHYTO-C Skincare Will Not Implicate in the Lawsuit 2Health News:DOMA Transforms Healthcare IT with Increased Security While Reducing Cost -- iCodeRx/iDocs/iCharts 6.0 Debuts at AHIMA National Convention 2Health News:DOMA Transforms Healthcare IT with Increased Security While Reducing Cost -- iCodeRx/iDocs/iCharts 6.0 Debuts at AHIMA National Convention 3Health News:Members to Benefit from New Agreement between Amerinet and B. E. Smith 2Health News:New Treatment May Beat Melanoma 2Health News:New Treatment May Beat Melanoma 3Health News:Surgery Best for Carpal Tunnel Syndrome 2Health News:Surgery Best for Carpal Tunnel Syndrome 3Health News:Antidepressants Linked to Heart Defects in Newborns 2Health News:Antidepressants Linked to Heart Defects in Newborns 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: